Obstructive sleep apnea (OSA) is a relatively common, chronic sleep disorder closely
related to type 2 diabetes mellitus (T2DM).
1
OSA is also related to cardiovascular disease development, representing a modifiable
cardiovascular risk factor.
2
It is an independent risk factor for coronary artery disease, cerebrovascular disease,
and all-cause mortality.
3
Therefore, its treatment, and preferably its primary prevention, seems to be of utmost
importance. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, a novel class of
antidiabetics, have revolutionized the treatment of patients with T2DM because they
exert cardio-protective and reno-protective beneficial effects.
4
Effects such as body weight reduction, osmotic diuresis leading to plasma volume
contraction, and suppression of sympathetic nervous system activity may be mechanisms
mediated by SGLT-2 inhibitors with potential useful implications for patients with
OSA or at high risk for OSA development. However, there is no evidence concerning
the role of SGLT-2 inhibitors in the prevention of OSA in patients with T2DM.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Obstructive sleep apnea and diabetes: a state of the art review.Chest. 2017; 152: 1070-1086
- Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association.Circulation. 2021; 144: e56-e67
- Obstructive sleep apnea and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies.Int J Cardiol. 2013; 169: 207-214
- Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.Sleep Breath. 2022;
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet. 2019; 393: 31-39
- The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME Trial.Diabetes Care. 2020; 43: 3007-3015
Article Info
Publication History
Published online: July 19, 2022
Received:
May 23,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
